ZyVersa Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
2436 NORTH FEDERAL HIGHWAY, LIGHTHOUSE POINT, FL, 33064
Mailing Address
2436 NORTH FEDERAL HIGHWAY, LIGHTHOUSE POINT, FL, 33064
Phone
908-370-5102
Fiscal Year End
1231
EIN
862685744
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| 8-K Current report of material events | December 3, 2025 | View on SEC |
| 8-K Current report of material events | November 19, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 19, 2025 | View on SEC |
| 8-K Current report of material events | October 15, 2025 | View on SEC |
| 8-K Current report of material events | September 18, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | August 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 13, 2025 | View on SEC |
| S-1/A IPO registration amendment | August 1, 2025 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Developing two promising drug platforms, VAR 200 and IC 100, licensed from the University of Miami.
- Platform-based approach designed to target multiple diseases, increasing potential for future pharmaceutical partnerships or buyouts.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.